Liver Disease
Study finds diet sodas raise liver disease risk as much as sugary ones
A large UK study has shown that both sugar-sweetened and low- or no-sugar soft drinks increase the risk of metabolic dysfunction-associated steatotic liver disease (MASLD). Consuming more than one can daily was linked to up to 60% higher odds of developing the condition. The findings, presented at UEG Week 2025, challenge the view of diet drinks as a healthier alternative.
Bile acids hinder liver cancer immunotherapy, supplement may help
Scientists at the Salk Institute have found that certain bile acids in the liver suppress immune cells, reducing the effectiveness of immunotherapy for liver cancer. Supplementing with ursodeoxycholic acid (UDCA) reversed this effect in mice, shrinking tumors. UDCA, already approved for other liver conditions, could soon enter clinical trials for cancer treatment.
Two common drugs show promise against fatty liver disease
由 AI 报道
Researchers at the University of Barcelona have discovered that combining two existing medications, pemafibrate and telmisartan, significantly reduces liver fat in animal models of metabolic dysfunction-associated steatotic liver disease (MASLD). This approach could offer a safer treatment option for the condition, which affects about one in three adults worldwide. The findings highlight the potential of drug repurposing to address a disease with limited current therapies.